Patents by Inventor John B. Hogenesch
John B. Hogenesch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210137911Abstract: The invention includes a formulation of a therapeutic compound, wherein release of the therapeutic compound from the formulation coincides with peak or trough expression of at least one target gene of the therapeutic compound. The invention also includes a method of developing such formulations and a method of treating a disorder in a subject using such formulations.Type: ApplicationFiled: January 20, 2021Publication date: May 13, 2021Inventors: John B. Hogenesch, Garret A. Fitzgerald
-
Publication number: 20210098121Abstract: The present disclosure relates to analyzing operational rhythms in hospital treatment and providing recommendations for hospital treatment based on the same. In an exemplary embodiment, a server comprises one or more processors; and memory comprising instructions that, when executed, cause the one or more processors to receive, from a database, treatment data corresponding to a treatment provided to a plurality of patients. The memory further comprises instructions that, when executed, cause the one or more processor to determine a preferred treatment regimen based upon the treatment data, wherein the preferred treatment regimen comprises a time of day the treatment is more effective than other times of the day based upon responses to the treatment. The memory also comprises instructions that, when executed, cause the one or more processor to provide a notification to a user interface to provide the treatment at the time of the day the treatment is more effective.Type: ApplicationFiled: September 30, 2020Publication date: April 1, 2021Inventors: Marc D. Ruben, John B. Hogenesch, David F. Smith
-
Publication number: 20180071272Abstract: The invention includes a formulation of a therapeutic compound, wherein release of the therapeutic compound from the formulation coincides with peak or trough expression of at least one target gene of the therapeutic compound. The invention also includes a method of developing such formulations and a method of treating a disorder in a subject using such formulations.Type: ApplicationFiled: October 19, 2015Publication date: March 15, 2018Inventors: JOHN B. HOGENESCH, GARRET A. FITZGERALD
-
Publication number: 20160186209Abstract: The invention provides recombinant cells comprising detectable reporters useful in identifying agents, genes, and other modulators of circadian period length and amplitude. Such modulators are useful for resetting the circadian clock in a variety of contexts (e.g., jet lag, shift work). Such cells are also useful in selecting an administration regimen for a therapeutic agent, where the agent's efficacy and/or adverse side effects show circadian effects.Type: ApplicationFiled: April 25, 2013Publication date: June 30, 2016Inventors: Andrew C. Liu, Chidambaram Ramanathan, John B. Hogenesch
-
Patent number: 8044025Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn IL Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.Type: GrantFiled: December 7, 2009Date of Patent: October 25, 2011Assignee: Research Development FoundationInventors: Wylie W. Vale, Jr., Teresa M. Reyes, Paul E. Sawchenko, Jean E. Rivier, Kathy A. Lewis, John B. Hogenesch, Joan M. Vaughan, Marilyn H. Perrin
-
Publication number: 20100168021Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn IL Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.Type: ApplicationFiled: December 7, 2009Publication date: July 1, 2010Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Wylie Walker Vale, JR., Teresa M. Reyes, Paul E. Sawchenko, Jean E. Rivier, Kathy A. Lewis, John B. Hogenesch, Joan M. Vaughan, Marilyn H. Perrin
-
Patent number: 7638607Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse CDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn IL Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.Type: GrantFiled: April 5, 2007Date of Patent: December 29, 2009Assignee: Research Development FoundationInventors: Wylie Walker Vale, Jr., Teresa M Reyes, Paul E Sawchenko, Jean E F Rivier, Kathy A Lewis, John B Hogenesch, Joan M Vaughan, Marilyn H Perrin
-
Publication number: 20090142793Abstract: Screening assays for identifying agents that modulate BK channel activity and further modulate the sleep/wake cycle in a subject, circadian regulated locomotor activity in a subject, or both are provided, as are agents identified using such screening assays. Also provided are methods of modulating the sleep/wake cycle in a subject and methods of modulating circadian regulated locomotor activity in a subject by administering an agent that modulates BK channel activity to the subject, for example, an agent identified by a screening assay as disclosed.Type: ApplicationFiled: September 23, 2008Publication date: June 4, 2009Inventors: Steve A. Kay, John B. Hogenesch, M. Fernanda Ceriani, Satchidananda Panda
-
Patent number: 7501489Abstract: The present invention provides isolated nucleic acids and proteins that are new and distinct members of the bHLH-PAS superfamily of transcription regulators. These “MOPs” (members of PAS) are useful in a variety of research, diagnostic and therapeutic applications. Several of the MOPs of the present invention are ?-class hypoxia-inducible factors. Several other of the MOPs of the invention are involved in circadian signal transduction.Type: GrantFiled: November 29, 2005Date of Patent: March 10, 2009Assignee: Wisconsin Alumni Research FoundationInventors: Christopher A. Bradfield, Yi Zhong Gu, John B. Hogenesch
-
Patent number: 7427489Abstract: Screening assays for identifying agents that modulate BK channel activity and further modulate the sleep/wake cycle in a subject, circadian regulated locomotor activity in a subject, or both are provided, as are agents identified using such screening assays. Also provided are methods of modulating the sleep/wake cycle in a subject and methods of modulating circadian regulated locomotor activity in a subject by administering an agent that modulates BK channel activity to the subject, for example, an agent identified by a screening assay as disclosed.Type: GrantFiled: June 17, 2003Date of Patent: September 23, 2008Assignees: The Scripps Research Institute, IRM LLCInventors: Steve A. Kay, John B. Hogenesch, M. Fernanda Ceriani, Satchidananda Panda
-
Patent number: 7344833Abstract: This invention provides novel AP-1 modulatory polypeptides. The invention also provides methods for screening modulators of AP-1 transcription factor activities. The methods comprise first screening test agents for modulators of an AP-1-modulatory polypeptide and then further screening the identified modulating agents for modulators of AP-1 transcription factor activities. The invention further provides methods and pharmaceutical compositions for modulating AP-1 transcription factor activities in a cell and for treating diseases and conditions mediated by abnormal cellular proliferation.Type: GrantFiled: November 5, 2003Date of Patent: March 18, 2008Assignee: IRM LLCInventors: Sumit Chanda, Suhaila White, John B. Hogenesch, Jeremy S. Caldwell
-
Patent number: 7223846Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn II. Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.Type: GrantFiled: October 25, 2004Date of Patent: May 29, 2007Assignee: Research Development FoundationInventors: Wylie Walker Vale, Jr., Teresa M Reyes, Paul E Sawchenko, Jean E F Rivier, Kathy A Lewis, John B Hogenesch, Joan M Vaughan, Marilyn H Perrin
-
Patent number: 7105647Abstract: The present invention provides isolated nucleic acids and proteins that are new and distinct members of the bHLH-PAS superfamily of transcription regulators. These “MOPs” (members of PAS) are useful in a variety of research, diagnostic and therapeutic applications. Several of the MOPs of the present invention are ?-class hypoxia-inducible factors. Several other of the MOPs of the invention are involved in circadian signal transduction.Type: GrantFiled: November 27, 1998Date of Patent: September 12, 2006Assignee: Wisconsin Alumni Research FoundationInventors: Christopher A. Bradfield, Yi Zhong Gu, John B. Hogenesch
-
Patent number: 6838274Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituituary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn II. Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.Type: GrantFiled: July 31, 2001Date of Patent: January 4, 2005Assignee: Research Development FoundationInventors: Wylie W. Vale, Jr., Teresa M. Reyes, Paul E. Sawchenko, Jean E. Rivier, Kathy A. Lewis, John B. Hogenesch, Joan M. Vaughan, Marilyn H. Perrin
-
Publication number: 20040171035Abstract: This invention provides novel p53 modulatory polypeptides. The invention also provides methods for screening modulators of p53. The methods comprise first screening test agents for modulators of a p53-modulatory polypeptide and then further screening the identified modulating agents for modulators of p53. The invention further provides methods and pharmaceutical compositions for modulating p53 bioactivities in a cell and for treating diseases and conditions mediated by abnormal cellular proliferation.Type: ApplicationFiled: November 7, 2003Publication date: September 2, 2004Applicants: IRM LLC, The Scripps Research InstituteInventors: Qihong Huang, Sumit Chanda, John B. Hogenesch, Jeremy S. Caldwell
-
Publication number: 20040146903Abstract: This invention provides novel AP-1 modulatory polypeptides. The invention also provides methods for screening modulators of AP-1 transcription factor activities. The methods comprise first screening test agents for modulators of an AP-1-modulatory polypeptide and then further screening the identified modulating agents for modulators of AP-1 transcription factor activities. The invention further provides methods and pharmaceutical compositions for modulating AP-1 transcription factor activities in a cell and for treating diseases and conditions mediated by abnormal cellular proliferation.Type: ApplicationFiled: November 5, 2003Publication date: July 29, 2004Applicant: IRM LLC, a Delaware Limited Liability CompanyInventors: Sumit Chanda, Suhaila White, John B. Hogenesch, Jeremy S. Caldwell
-
Publication number: 20040076954Abstract: Methods for identifying responder genes and regulatory regions that confer responsiveness to a test substance or other perturbation are provided. Regulatory regions identified by such methods or other methods are cloned into expression constructs to control expression of a nucleic acid molecule that encodes, for example, a selectable marker or reporter, and introduced into cells. The resulting cells are used, for example, in high throughput screening assays for profiling substances and conditions and for studying the function of the regulatory region mediating the response. Addressable collections of the cells are also provided.Type: ApplicationFiled: March 12, 2002Publication date: April 22, 2004Applicant: IRM, LLCInventors: Jeremy S. Caldwell, John B. Hogenesch, Andrew I. Su
-
Publication number: 20030170642Abstract: A genetic screening methodology for rapid identification of candidate targets of any small molecule cellular effectors and other signals and modulators of cellular functions and pathways is provided. The effect of a small molecule or other signal on a cell is titrated by expressing within the cell cDNA that encodes a polypeptide that is the molecular target or that is responsible for directly or indirectly producing the molecular target.Type: ApplicationFiled: March 12, 2002Publication date: September 11, 2003Applicant: IRM, LLCInventors: Jeremy S. Caldwell, Sumit K. Chanda, Nikunj V. Somia, John B. Hogenesch, Michael P. Cooke, Pedro Aza-Blanc
-
Publication number: 20020127221Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn II. Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.Type: ApplicationFiled: July 31, 2001Publication date: September 12, 2002Inventors: Wylie W. Vale, Teresa M. Reyes, Paul E. Sawchenko, Jean E. Rivier, Kathy A. Lewis, John B. Hogenesch, Joan M. Vaughan, Marilyn H. Perrin